Results 71 to 80 of about 18,827 (200)

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer

Nature Communications
Cyclin-dependent kinases 4 and 6 (CDK4/6) play a pivotal role in cell cycle and cancer development. Targeting CDK4/6 has demonstrated promising effects against breast cancer.
Yi Zhang, Shuyan Zhou, Yan Kai, Ya-qin Zhang, Changmin Peng, Zhuqing Li, Muhammad Jameel mughal, Belmar Julie, Xiaoyan Zheng, Junfeng Ma, Cynthia X. Ma, Min Shen, Matthew D. Hall, Shunqiang Li, Wenge Zhu   +14 more
doaj   +1 more source

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

International Journal of Cancer, Volume 159, Issue 10, Page 2393-2402, 15 November 2026.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

BMC Cancer
Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors (CDK4/6i).
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group   +11 more
doaj   +1 more source

Profile of palbociclib in the treatment of metastatic breast cancer

, 2016
Moataz Ehab,1 Mohamad Elbaz2,31Department of Pharmacy Practice, 2Department of Pharmacology, Pharmacy School, Helwan University, Egypt; 3Department of Pathology, The Comprehensive Cancer Center, The Ohio State University Wexner Medical Center ...
Ehab M, Elbaz M
core  

Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS

Biomedical Chromatography, Volume 40, Issue 10, October 2026.
ABSTRACT CDC‐like kinases (CLK) and dual‐specificity tyrosine‐regulated kinases (DYRK) are protein kinases involved in various cellular functions, mRNA splicing, and DNA damage repair. CLK/DYRK kinases have been implicated in many disorders such as diabetes, neurodegenerative diseases, and cancer.
Julianne L. Holleran, Joshua J. Deppas, Ye Feng, Michael J. Hochman, Evan C. Chen, Maximilian Stahl, Steven D. Gore, Timothy W. Synold, Jan H. Beumer, Raman Venkataramanan, Robert A. Parise   +10 more
wiley   +1 more source

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination

Advances in Radiation Oncology, 2019
Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, the ...
Mudit Chowdhary, MD, Neilayan Sen, MD, Akansha Chowdhary, MD, Lydia Usha, MD, Melody A. Cobleigh, MD, Dian Wang, MD, PhD, Kirtesh R. Patel, MD, Parul N. Barry, MD, Ruta D. Rao, MD   +8 more
doaj   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

, 2014
Karen A Cadoo, Ayca Gucalp, Tiffany A TrainaBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USAAbstract: Cellular proliferation, growth, and division following DNA ...
Gucalp A, Traina TA, Cadoo KA
core  

Oral ulcers in patients treated with palbociclib: a case report

, 2018
Introduction: Palbociclib is an approved drug in the treatment of women with advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, breast cancer.
Jean-Christophe Fricain, Cédric Alande, Mathilde Fénélon   +2 more
core   +1 more source

Genetic variant within CDK6 regulates immune response to palbociclib treatment

, 2022
Everyone carries a set of genetic variants that contribute to regulation of the levels of blood cells, with unknown clinical impact. One of them, rs445 within the cell-cycle checkpoint gene CDK6, reduces the levels of myeloid cell types including ...
Orru V., Steri M., Zoledziewska M., Fiorillo E., Serra V., Cucca F.   +5 more
core   +1 more source